{"id":"iron-sucrose-erythropoietin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Thrombotic events"},{"rate":null,"effect":"Hyperkalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Iron sucrose provides bioavailable iron necessary for hemoglobin synthesis, while erythropoietin (EPO) is a recombinant cytokine that stimulates erythropoiesis by binding to EPO receptors on bone marrow progenitor cells. Together, they address both iron deficiency and EPO-responsive anemia, common complications in chronic kidney disease and dialysis patients.","oneSentence":"Iron sucrose replenishes iron stores while erythropoietin stimulates red blood cell production to treat anemia in patients with chronic kidney disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:13.157Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia in patients with chronic kidney disease on dialysis"},{"name":"Iron deficiency anemia in chronic kidney disease patients"}]},"trialDetails":[{"nctId":"NCT00239616","phase":"PHASE2","title":"Pharmacokinetic of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving Epoetin","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2002-06-05","conditions":"Anemia","enrollment":10},{"nctId":"NCT06968936","phase":"NA","title":"Perioperative Blood Conservation: Role of Combined Iron Supplementation Protocols in Reducing Allogeneic Transfusion","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-05-15","conditions":"Anemia, Iron Deficiencies, Cardiac Surgery","enrollment":400},{"nctId":"NCT00236964","phase":"PHASE3","title":"Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on Dialysis","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2001-02-23","conditions":"Anemia","enrollment":96},{"nctId":"NCT06012760","phase":"NA","title":"The Effect of Combined Iron Protocols on Perioperative Allogeneic Transfusion","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-01-04","conditions":"Anemia, Iron Deficiency Anemia, Perioperative","enrollment":400},{"nctId":"NCT05353348","phase":"NA","title":"Effect of the Combined Programme on Perioperative Anaemia（CPPA）","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03-15","conditions":"Patient Blood Management, Cardiac Surgery, Iron Deficiency Anemia","enrollment":110},{"nctId":"NCT05734716","phase":"PHASE4","title":"Colorado-Oregon Altitude Study","status":"COMPLETED","sponsor":"University of Oregon","startDate":"2021-02-17","conditions":"Acute Mountain Sickness","enrollment":121},{"nctId":"NCT04141631","phase":"NA","title":"Transfusion Savings in Heart Surgery: Impact of Individual Strategy by Erythropoietin and Metabolic Adjustment (ScvO2)","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2020-01-13","conditions":"Cardiac Surgery, Transfusion, Perioperative Anemia","enrollment":128},{"nctId":"NCT01414075","phase":"PHASE2","title":"Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2011-07-21","conditions":"Dialysis, Anemia","enrollment":60},{"nctId":"NCT03528564","phase":"PHASE2","title":"Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia","status":"TERMINATED","sponsor":"Unity Health Toronto","startDate":"2019-07-01","conditions":"Anemia, Iron Deficiency, Anemia of Chronic Disease, Hip Arthropathy","enrollment":4},{"nctId":"NCT00236938","phase":"PHASE3","title":"Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2002-07","conditions":"Anemia","enrollment":121},{"nctId":"NCT02707757","phase":"PHASE4","title":"Treatment Response in Dialysis Anaemia","status":"COMPLETED","sponsor":"Imperial College Healthcare NHS Trust","startDate":"2015-07","conditions":"Anaemia, Haemodialysis","enrollment":197},{"nctId":"NCT04464850","phase":"PHASE3","title":"Intravenous Versus Oral Iron Therapy in Hemodialysis Patients","status":"UNKNOWN","sponsor":"Chiang Mai University","startDate":"2020-07-29","conditions":"Hemodialysis Complication, Anemia, Iron Deficiency Anemia","enrollment":124},{"nctId":"NCT02060851","phase":"PHASE4","title":"Effects of Early Short-term Intravenous Iron Supplements Combined EPO in Preterm Infants","status":"COMPLETED","sponsor":"Kunshan First People's Hospital Affiliated to Jiangsu University","startDate":"2014-02","conditions":"Malnutrition","enrollment":96},{"nctId":"NCT03214627","phase":"NA","title":"Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial","status":"TERMINATED","sponsor":"Vifor Fresenius Medical Care Renal Pharma","startDate":"2018-12-10","conditions":"Anemia, End Stage Renal Disease","enrollment":88},{"nctId":"NCT03658876","phase":"PHASE4","title":"Predictors of Response to Iron and Erythropoietin Stimulating Agents","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-06-03","conditions":"Renal Failure Chronic, Anemia","enrollment":197},{"nctId":"NCT03917394","phase":"","title":"Erythropoietin And/Or Iron Sucrose For Perioperative Anemia Management In Hip and Knee Arthroplasty","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-04-24","conditions":"Anemia, Iron Deficiency","enrollment":780},{"nctId":"NCT02390102","phase":"PHASE3","title":"Erythropoietin + Iron Therapy for Anemic Patients Undergoing Aortic Valve Replacement","status":"COMPLETED","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2012-06","conditions":"Anemia, Aortic Stenosis","enrollment":117},{"nctId":"NCT00236951","phase":"PHASE3","title":"Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2003-02","conditions":"Anemia","enrollment":224},{"nctId":"NCT03317210","phase":"PHASE4","title":"Intravenous Treatment of Anemia in Pregnancy","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2002-09-01","conditions":"Anemia","enrollment":50},{"nctId":"NCT00318812","phase":"PHASE2, PHASE3","title":"Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2007-05","conditions":"Anemia, Renal Failure","enrollment":55},{"nctId":"NCT01888003","phase":"NA","title":"The Benefits of a Preoperative Anemia Management Program","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2013-04","conditions":"Anemia, Iron-Deficiency","enrollment":51},{"nctId":"NCT01975844","phase":"PHASE4","title":"The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability","status":"TERMINATED","sponsor":"Michael Germain","startDate":"2013-07","conditions":"Anemia, End Stage Renal Disease","enrollment":48},{"nctId":"NCT00482716","phase":"PHASE3","title":"Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer","status":"UNKNOWN","sponsor":"St. Bartholomew's Hospital","startDate":"2007-01","conditions":"Anemia, Leukemia, Lymphoma","enrollment":80},{"nctId":"NCT01012063","phase":"NA","title":"Perioperative Iron With Erythropoietin in Bilateral Total Knee Replacement Arthroplasty (TKRA)","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2008-08","conditions":"Anemia, Transfusion","enrollment":54},{"nctId":"NCT00223964","phase":"PHASE4","title":"Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2003-06","conditions":"Anemia","enrollment":59},{"nctId":"NCT00224042","phase":"PHASE4","title":"Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2003-04","conditions":"Anemia, Iron-Deficiency, Kidney Failure, Chronic","enrollment":52},{"nctId":"NCT00661999","phase":"PHASE3","title":"Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2006-01","conditions":"Anemia, Leukemia, Lymphoma","enrollment":502},{"nctId":"NCT00557817","phase":"PHASE2, PHASE3","title":"Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)","status":"COMPLETED","sponsor":"University of Liege","startDate":"2004-03","conditions":"Hematological Malignancies","enrollment":125},{"nctId":"NCT00224003","phase":"PHASE4","title":"Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2003-04","conditions":"Anemia","enrollment":23},{"nctId":"NCT00145652","phase":"PHASE3","title":"Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders.","status":"COMPLETED","sponsor":"Sundsvall Hospital","startDate":"2003-12","conditions":"Anemia, Multiple Myeloma, Non Hodgkin Lymphoma","enrollment":66},{"nctId":"NCT00210002","phase":"PHASE2","title":"Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced","status":"TERMINATED","sponsor":"Institut Claudius Regaud","startDate":"2003-11","conditions":"Neoplasms, Anemia","enrollment":55},{"nctId":"NCT00204256","phase":"PHASE4","title":"Intravenous Iron in Patients With Anemia of Chronic Kidney Disease","status":"UNKNOWN","sponsor":"University Hospital Muenster","startDate":"2004-03","conditions":"Kidney Failure, Chronic","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":181,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Venofer"],"phase":"phase_3","status":"active","brandName":"Iron Sucrose + Erythropoietin","genericName":"Iron Sucrose + Erythropoietin","companyName":"American Regent, Inc.","companyId":"american-regent-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iron sucrose replenishes iron stores while erythropoietin stimulates red blood cell production to treat anemia in patients with chronic kidney disease. Used for Anemia in patients with chronic kidney disease on dialysis, Iron deficiency anemia in chronic kidney disease patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}